NASDAQ:ELVN Enliven Therapeutics Q3 2026 Earnings Results & Report $44.79 -2.46 (-5.21%) Closing price 11/5/2026 04:00 PM EasternExtended Trading$44.74 -0.05 (-0.11%) As of 11/5/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Enliven Therapeutics beat analyst earnings expectations in its Q3 2026 results, released November 5, 2026. The company reported EPS of -$0.36 versus the -$0.4479 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 5, 2026TimeAfter Market ClosesConference Call4:00 PM ET Enliven Therapeutics EPS ResultsActual EPS-$0.36Consensus EPS -$0.4479Beat/MissBeat by +$0.0879One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersEnliven Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Enliven Therapeutics Q3 2026 Earnings FAQ Did Enliven Therapeutics beat earnings estimates for Q3 2026? Enliven Therapeutics (NASDAQ:ELVN) reported earnings of -$0.36 per share for Q3 2026, beating the consensus estimate of -$0.4479. The report was announced on Thursday, November 5, 2026. Enliven Therapeutics Earnings HeadlinesEnliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business UpdateNovember 5 at 4:05 PM | prnewswire.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Stock Has Consensus Target Price of $75.44 According to BrokeragesNovember 3 at 3:45 AM | americanbankingnews.comMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a household name. Now he says a similar shift is unfolding in AI infrastructure. Hundreds of billions are pouring into AI data centers, but he warns the builders could get crushed by their own costs while one overlooked sector absorbs the spending. | Porter & Company (Ad)Enliven Therapeutics (NASDAQ:ELVN) Stock Price Breaks Above 200-Day Moving Average - Time to Sell?October 28, 2026 | americanbankingnews.comTD Cowen Remains a Buy on Enliven Therapeutics (ELVN)October 25, 2026 | theglobeandmail.comEnliven Therapeutics, Inc. Announces Appointment of Kristine Ball to Board of Directors, Effective October 14, 2026October 15, 2026 | marketscreener.comMSee More Enliven Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Enliven Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enliven Therapeutics and other key companies, straight to your email. Email Address About Enliven TherapeuticsEnliven Therapeutics (NASDAQ:ELVN) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes. Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors. Both programs are being evaluated in clinical development, and the company may expand its pipeline through additional internally discovered oncology programs. Enliven Therapeutics is based in Boulder, Colorado, and focuses primarily on the development of medicines for cancer patients in the United States and other potential international markets. The company was co-founded by Sam Kintz, who serves as its chief executive officer.View Enliven Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to WatchQualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a CatchUber's Profit Drop: A Speed Bump or Structural Shift?Boeing Has the Orders, the Cash Flow, and Insider Buyers, But What's Still Missing?Keurig Dr Pepper's Beverage Growth Raises a Tough Question About Its Coffee SplitAmazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?Datadog's Post-Earnings Sell-Off: A Buying Opportunity in Plain Sight? Upcoming Earnings Occidental Petroleum (11/9/2026)KKR & Co. Inc. (11/9/2026)Barrick Mining (11/9/2026)Constellation Energy (11/9/2026)Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026)Honda Motor (11/11/2026)Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
